U.S. Pat. Appln. Serial No.: 10/561,055

Group Art Unit No.: 1621

## **Amendments to the Claims**

This listing of claims will replace all prior versions, and listings, of claims in the above-identified application.

## **Listing of Claims**:

1. (Cancelled).

2. (Previously Presented). A compound of formula (la):

$$R^{12}$$
OH
SO<sub>2</sub>R<sup>10</sup>
(Ia)

wherein:

R<sup>10</sup> represents H or C<sub>1-6</sub> alkyl;

 $\mathsf{R}^{12}$  represents H, halo,  $\mathsf{CF}_3$ , cyano,  $\mathsf{OCF}_3$ , nitro,  $\mathsf{OR}^{13}$ ,  $\mathsf{SR}^{13}$ ,  $\mathsf{COR}^{13}$  or  $\mathsf{C}_{1\text{-}6}$  alkyl;

R<sup>13</sup> represents C<sub>1-6</sub> alkyl or C<sub>1-4</sub>alkylaryl;

and physiologically functional derivatives thereof.

- 3. (Cancelled).
- 4. (Cancelled).
- 5. (Cancelled).
- 6. (Previously Presented). A pharmaceutical composition comprising a compound of claim 2, and pharmaceutically acceptable carriers or diluents.

U.S. Pat. Appln. Serial No.: 10/561,055

Group Art Unit No.: 1621

7. **(Currently Amended)**. A process for preparation of compounds of formula (la) of claim 2, which comprises:

## (A) reacting a compound of formula (II):

$$L-Q$$
 $N$ 
 $R^2$ 
 $(II)$ 

wherein:

R<sup>2</sup> is SO<sub>2</sub>R<sup>10</sup>, wherein R<sup>10</sup> is as defined in claim 2;


Q is phenyl;

X is CO<sub>2</sub>H; and

L represents a leaving group,

with a reagent suitable to introduce phenyl optionally substituted by R<sup>12</sup>, wherein R<sup>12</sup> is as defined in claim 2; or a compound of formula (IV):

## (H) reacting a compound of formula (VI)



or a protected derivative thereof, wherein:

R<sup>1</sup> is phenyl optionally substituted by R<sup>12</sup>,

wherein R<sup>12</sup> us as defined in claim 2,

Z is a bond,

Q is phenyl and

X is CO<sub>2</sub>H

with a reagent suitable to introduce the group  $\underline{SO_2R^{10}}$   $\underline{CO_2H}$ , wherein  $R^{10}$  is as defined in claim 2; or

- (J) carrying out a process selected from processes (A) to (H) followed by interconversion of one or more functional groups.
- 8.(Currently Amended). The pharmaceutical composition according to claim 6 further comprising one or more therapeutic agents, selected from anti-inflammatory agents, NSAIDs. beta adrenergic agents and anti-infective agents, wherein:

U.S. Pat. Appln. Serial No.: 10/561,055 Group Art Unit No.: 1621

the anti-inflammatory agents are selected from corticosteroids selected from fluticasone propionate, beclomethasone dipropionate, mometasone furoate, triamcinolone acetonide or budesonide};

the NSAIDs are selected from sodium cromoglycate, nedocromil sodium, PDE-4 inhibitors, leukotriene antagonists, CCR-3 antagonists, iNOS inhibitors, tryptase and elastase inhibitors, beta-2 integrin antagonists and adenosine 2a agonists;

the beta adrenergic agents are selected from salmeterol, salbutamol, formoterol, fenoterol or terbutaline and salts thereof; or

the anti-infective agents are selected from antibiotics or antivirals.